LAVA Therapeutics N.V. (LVTX)

Market Cap	23.98M
Revenue (ttm)	7.35M
Net Income (ttm)	-27.64M
Shares Out	26.30M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,151
Open	0.960
Previous Close	0.956
Day's Range	0.912 - 0.960
52-Week Range	0.881 - 6.470
Beta	0.56
Analysts	Buy
Price Target	3.33 (+265.21%)
Earnings Date	Mar 19, 2025

About LVTX

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candida...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2021
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: LVTX
• Website: https://www.lavatherapeutics.com

Financial Performance

In 2023, LAVA Therapeutics's revenue was $6.77 million, a decrease of -65.09% compared to the previous year's $19.39 million. Losses were -$41.97 million, 31.6% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for LVTX stock is "Buy." The 12-month stock price forecast is $3.33, which is an increase of 265.21% from the latest price.

Price Target

$3.33

(265.21% upside)

Analyst Consensus: Buy